A suite of drugs developed by the Cancer Therapeutics Cooperative Research Centre (CTx) from early Monash research has been licensed to global healthcare leader Merck (MSD).
The drugs have potential clinical applications in both cancer and non-cancer blood disorders. This was a significant licensing deal involving an Australian discovery and will ensure that this knowledge is translated for the benefit of patients.
The project focused on the discovery and development of novel therapies for cancer, first discovered by Professor Stephen Jane, Head of the Monash Central Clinical School. The drugs were further developed by CTx, a Melbourne based Cooperative Research Centre in collaboration with Professor Susan Charman, Director of the Centre for Drug Candidate Optimisation within the Monash Institute of Pharmaceutical Sciences, with support from the Wellcome Trust.
Under the terms of the license, MSD will be responsible for research and development, including clinical development, and for worldwide commercialisation of products.
See related story: Monash discovery at heart of record breaking licensing deal